West Pharmaceutical Services Inc. (WST) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
West Pharmaceutical Services’s revenue went from $1.5B in fiscal 2016 to $3.1B in fiscal 2025, growth of about 8.2% a year.
Net income in fiscal 2025 was $494M, a net margin of 16.1%; the best year in this period was 2021 with $662M.
Over the twelve months to September 30, 2026, revenue was $3.4B and net income $639M.
Free cash flow was $469M in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 3% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4B | $3.1B | $2.9B | $2.9B | $2.9B | $2.8B | $2.1B | $1.8B | $1.7B | $1.6B | $1.5B |
| Gross profit | $1.3B | $1.1B | $998M | $1.1B | $1.1B | $1.2B | $768M | $606M | $545M | $513M | $501M |
| Operating income | $780M | $585M | $570M | $676M | $734M | $752M | $407M | $297M | $240M | $226M | $195M |
| Net income | $639M | $494M | $493M | $593M | $586M | $662M | $346M | $242M | $207M | $151M | $144M |
| EPS (diluted) | $8.91 | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 | $1.99 | $1.91 |
| R&D | $76M | $74M | $69M | $68M | $58M | $53M | $47M | $39M | $40M | $39M | $37M |
| Revenue growth | — | +6.2% | −1.9% | +2.2% | +1.9% | +31.9% | +16.7% | +7.1% | +7.4% | +6.0% | +7.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $654M | $755M | $653M | $776M | $724M | $584M | $472M | $367M | $289M | $263M | $219M |
| Capital spending | -$201M | -$286M | -$377M | -$362M | -$285M | -$253M | -$174M | -$126M | -$105M | -$131M | -$170M |
| Free cash flow | $453M | $469M | $276M | $414M | $439M | $331M | $298M | $241M | $184M | $132M | $49M |
| Dividends paid | $63M | $61M | $59M | $57M | $54M | $51M | $48M | $45M | $42M | $39M | $36M |
| Buybacks | $685M | $134M | $561M | $438M | $203M | $137M | $116M | $83M | $71M | $74M | $52M |
| Stock-based pay | $28M | $24M | $19M | $23M | $24M | $38M | $34M | $24M | $15M | $16M | $20M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $791M | $485M | $854M | $894M | $763M | $616M | $439M | $337M | $236M | $203M |
| Debt | — | $321M | $302M | $309M | $318M | $325M | $326M | $329M | $196M | $197M | $229M |
| Equity | — | $3.2B | $2.7B | $2.9B | $2.7B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B | $1.1B |
| Total assets | — | $4.3B | $3.6B | $3.8B | $3.6B | $3.3B | $2.8B | $2.3B | $2.0B | $1.9B | $1.7B |
| Shares (diluted) | 71M | 73M | 74M | 75M | 76M | 76M | 76M | 75M | 75M | 76M | 75M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 37.6% | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% | 35.8% | 32.9% | 31.8% | 32.1% | 33.2% |
| Operating margin | 23.0% | 19.0% | 19.7% | 22.9% | 25.4% | 26.6% | 18.9% | 16.1% | 14.0% | 14.1% | 12.9% |
| Net margin | 18.8% | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% | 9.4% | 9.5% |
| FCF margin | 13.3% | 15.2% | 9.6% | 14.1% | 15.2% | 11.7% | 13.9% | 13.1% | 10.7% | 8.3% | 3.3% |
| ROIC | — | 13.3% | 15.6% | 17.5% | 20.3% | 24.2% | 15.3% | 12.4% | 12.5% | 9.7% | 10.3% |
| ROE | — | 15.5% | 18.4% | 20.6% | 21.8% | 28.3% | 18.7% | 15.4% | 14.8% | 11.8% | 12.8% |
Frequently asked questions
What is West Pharmaceutical Services’s annual revenue?
$3.1B in fiscal 2025 and $3.4B over the twelve months to September 30, 2026.
How much profit does West Pharmaceutical Services make?
Net income was $494M in fiscal 2025 (net margin 16.1%).
Is West Pharmaceutical Services’s revenue growing?
Yes: revenue rose 6.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.